Corient Private Wealth LLC Sells 5,352 Shares of Solventum Co. (NYSE:SOLV)

Corient Private Wealth LLC reduced its position in Solventum Co. (NYSE:SOLV) by 9.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 54,269 shares of the company’s stock after selling 5,352 shares during the quarter. Corient Private Wealth LLC’s holdings in Solventum were worth $3,585,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of SOLV. Hotchkis & Wiley Capital Management LLC bought a new stake in shares of Solventum in the 3rd quarter valued at $125,488,000. Trian Fund Management L.P. boosted its stake in shares of Solventum by 32.9% in the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after purchasing an additional 1,765,676 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Solventum in the 3rd quarter valued at $50,948,000. Nordea Investment Management AB lifted its position in shares of Solventum by 189.5% during the 4th quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock valued at $43,902,000 after acquiring an additional 431,986 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Solventum during the 4th quarter valued at $18,583,000.

Analysts Set New Price Targets

A number of research analysts recently issued reports on SOLV shares. Wells Fargo & Company boosted their target price on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Mizuho boosted their target price on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Morgan Stanley boosted their target price on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th. Bank of America boosted their target price on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. Finally, The Goldman Sachs Group upped their price objective on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, Solventum has an average rating of “Hold” and a consensus price target of $79.86.

Solventum Stock Performance

Shares of SOLV stock opened at $74.00 on Friday. The firm has a 50-day moving average of $75.17 and a 200-day moving average of $71.56. The company has a market cap of $12.80 billion and a P/E ratio of 26.91. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a one year low of $47.16 and a one year high of $85.92.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.